論文

査読有り
2021年

Claudin-5: A Pharmacological Target to Modify the Permeability of the Blood-Brain Barrier.

Biological & pharmaceutical bulletin
  • Yosuke Hashimoto
  • ,
  • Matthew Campbell
  • ,
  • Keisuke Tachibana
  • ,
  • Yoshiaki Okada
  • ,
  • Masuo Kondoh

44
10
開始ページ
1380
終了ページ
1390
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1248/bpb.b21-00408

Claudin-5 is the dominant tight junction protein in brain endothelial cells and exclusively limits the paracellular permeability of molecules larger than 400 Da across the blood-brain barrier (BBB). Its pathological impairment or sustained down-regulation has been shown to lead to the progression of psychiatric and neurological disorders, whereas its expression under physiological conditions prevents the passage of drugs across the BBB. While claudin-5 enhancers could potentially act as vascular stabilizers to treat neurological diseases, claudin-5 inhibitors could function as delivery systems to enhance the brain uptake of hydrophilic small-molecular-weight drugs. Therefore, the effects of claudin-5 manipulation on modulating the BBB in different neurological diseases requires further examination. To manipulate claudin-5 expression levels and function, several claudin-5 modulating molecules have been developed. In this review, we first describe the molecular, cellular and pathological aspects of claudin-5 to highlight the mechanisms of claudin-5 enhancers/inhibitors. We then discuss recently developed claudin-5 enhancers/inhibitors and new methods to discover these molecules.

リンク情報
DOI
https://doi.org/10.1248/bpb.b21-00408
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34602546
ID情報
  • DOI : 10.1248/bpb.b21-00408
  • PubMed ID : 34602546

エクスポート
BibTeX RIS